Brief: Medicenna Therapeutics Says Funds Available Sufficient To Complete Mdna55 Phase 2b Clinical Study
25/06/2019 22:20
June 25 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA THERAPEUTICS CORP - HAS FUNDS AVAILABLE OF
US$2.3
MILLION REMAINING ON GRANT FROM CANCER PREVENTION AND RESEARCH
INSTITUTE OF TEXAS
* MEDICENNA THERAPEUTICS - FUNDS AVAILABLE ARE SUFFICIENT TO
COMPLETE MDNA55 PHASE 2B CLINICAL STUDY AND PLANNED END OF PHASE
2 MEETING WITH U.S. FDA
Source text for Eikon: ID:nCNW4cQp8a
Further company coverage: MDNA.TO
((Reuters Messaging: Reuters.Briefs@thomsonreuters.com))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results